Komorbid Kardiovaskular dan Gastrointestinal pada Coronavirus Disease 2019 (COVID-19)
DOI:
https://doi.org/10.35790/msj.v4i2.45013Abstract
Abstract: COVID-19 patients have various clinical characteristics. Patients who come with co-morbidities are more at risk of experiencing more severe symptoms and higher risk of death. This study aimed to obtain cardiovascular and gastrointestinal comorbidities of coronavirus disease-2019 (COVID-19). This was a literature review study. The literature search was performed by using ScienceDirect, PubMed and Clinical key databases with “Comorbid AND Cardiovascular AND COVID-19” and “Comorbid AND Gastrointestinal AND COVID-19” for the keywords. After searching and filtering the literatures based on inclusion and exclusion criteria, finally 10 literatures were determined to be reviewed. The ten literature reviews showed that COVID-19 patients had cardiovascular comorbidities including hypertension, coronary heart disease (CHD), heart failure, and atrial fibrillation. Gastrointestinal comorbidities found include chronic gastritis, peptic ulcer, gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel disease, diverticular disease, gastrointestinal tumors and polyps. In conclusion, patients with COVID-19 have varieties of comorbidities, and the most common one is hypertension and GERD.
Keywords: cardiovascular comorbidity; gastrointestinal comorbidity; COVID-19
Abstrak: Pasien COVID-19 memiliki karakteristik klinis yang beragam. Pasien dengan penyakit penyerta lebih berisiko mengalami gejala yang lebih berat dan risiko kematian lebih tinggi. Penelitian ini bertujuan untuk mengetahui komorbid kardiovaskular dan gastrointestinal dari coronavirus disease-2019 (COVID-19). Penelitian dilakukan menggunakan metode literature review. Pencarian literatur dilakukan pada tiga database yaitu PubMed, ScienceDirect dan ClinicalKey dengan kata kunci “Comorbid AND Cardiovascular AND COVID-19” serta “Comorbid AND Gastrointestinal AND COVID-19”. Setelah melalui proses pencarian dan penyaringan literatur berdasarkan kriteria inklusi dan ekslusi, akhirnya ditetapkan 10 literatur untuk ditelaah. Hasilnya sebanyak sepuluh tinjauan literatur menunjukkan pasien COVID-19 memiliki komorbid kardiovaskular antara lain hipertensi, penyakit jantung koroner (PJK), gagal jantung, dan fibrilasi atrial. Komorbid gastrointestinal yang ditemukan antara lain gastritis kronik, ulkus peptikum, gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel disease, diverticular disease, tumor dan polip saluran cerna. Simpulan penelitian ini ialah pasien dengan COVID-19 memiliki berbagai jenis komorbid, dan yang terutama ialah hipertensi dan GERD.
Kata kunci: komorbid kardiovaskular; komorbid gastrointestinal; COVID-19
References
Rauf A, Abu-Izmeid T, Olatunde A, Khalil AA, Alhumaydhi FA, Tufail T, et al. COVID-19 pandemic: epidemiology, etiology, conventional and non-conventional therapies. International Journal of Environmental Research and Public Health (IJERPH). 2020;17(21):1-32.
Velavan T, Meyer C. The COVID-19 epidemic. Trop Med Int Health. 2020;25(3):278-80.
WHO. Update on coronavirus disease in Indonesia. Available from: https://www.who.int/indonesia/ news/novel-coronavirus
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.
Mesquita RR, Junior LCFS, Santana FMS, Oliveira TF, Alcantara RC, Arnozo GM, et al. Clinical manifestations of COVID-19 in the general population: systematic review. The Central European Journal of Medicine (CEJMED). 2021;133(7-8):377-82.
Hsing TP, Lai YW, Lin YY, Luo YH, Lin YT, Chen HK, et al. Clinical manifestation and disease progression in COVID-19 infection. J Chin Med Assoc. 2021;84(1):3-8.
Wang X, Fang X, Cai Z, Wu X, Gao X, Min J, et al. Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: a systemic review and meta-analysis. Research (Wash DC). 2020;2020:2409621. p.1-17. Doi: 10.34133/ 2020/2402961.
Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. J Community Empowerment Health. 2020;3(2):77-84.
Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833-9.
Mai F, Pinto RD, Ferri C. COVID-19 and cardiovascular diseases. J Cardiol. 2020;76(5):453-8.
Hua S, Yang Y, Zou D, Li J, Yan K, Xu Y, et al. COVID-19 and metabolic comorbidities: an update on emerging evidences for optimal therapies. Biomedicine and Pharmacotherapy. 2021;140:111685.
Liang W, Feng Z, Rao S, Xiao C, Xue X, Lin Z, et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut. 2020 1;69(6):1141-3.
Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;75(7):1730-41.
Salinas-Botrán A, Sanz-Cánovas J, Pérez-Somarriba J, Pérez-Belmonte LM, Cobos-Palacios, Rubio-Rivas M, et al. Clinical characteristics and risk factors for mortality upon admission in patients with heart failure hospitalized due to COVID-19 in Spain. Rev Clin Esp (Barc). 2022;222(5):255-65.
Salinas-Aguirre JE, Sánchez-García C, Rodríguez-Sanchez R, Rodríguez-Muñoz L, Díaz-Castaño A, Bernal-Gómez R. Clinical characteristics and comorbidities associated with mortality in patients with COVID-19 in Coahuila (Mexico). Rev Clin Esp (Barc). 2022;222(5):288-92.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area [published correction appears in JAMA. 2020 May 26;323(20):2098]. JAMA. 2020;323(20):2052-2059.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054-62.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China [published correction appears in JAMA. 2021 Mar 16;325(11):1113]. JAMA. 2020;323(11):1061-9.
Laszkowska M, Faye AS, Kim J, Truong H, Silver ER, Ingram M, et al. Disease course and outcomes of COVID-19 among hospitalized patients with gastrointestinal manifestations. Clin Gastroenterol Hepatol. 2021;19(7):1402-9.e1.
Queiroz NSF, Martins CA, Quaresma AB, Hino AAF, Steinwurz F, Ungaro RC, et al. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry. J Gastroenterol Hepatol. 2021;36(11):3033-40.
Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020;69(7):1213-7.
Hajifathalian K, Krisko T, Mehta A, Kumar S, Schwartz R, Fortune B, et al. Gastrointestinal and hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients from New York: clinical implications. Gastroenterology. 2020;159(3):1137-40.e2.
Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2020; 52(2):276-283.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Emmanuella E. N. A Somalinggi, Frans E. N. Wantania, Bradley J. Waleleng
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
COPYRIGHT
Authors who publish with this journal agree to the following terms:
Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.
Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.
Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).
